Lilly plans to open Lilly Gateway Labs site in Philadelphia

Written By :  Ruchika Sharma
Published On 2025-11-24 05:00 GMT   |   Update On 2025-11-24 05:00 GMT
Advertisement

Indianapolis: Eli Lilly and Company has announced plans to open a new Lilly Gateway Labs site in Philadelphia.

The new Gateway Labs site will occupy 44,000 square feet of 2300 Market, a life sciences facility in Center City newly developed and operated by Breakthrough Properties.

As per the release, Biotechs based in the site will have access to fully equipped wet lab facilities alongside the scientific engagement that has been the hallmark of the Gateway Labs approach.

Advertisement

"Philadelphia has long led biotech innovation, from early vaccine development to pioneering gene therapy and CAR-T treatments and discovering new approaches to Alzheimer's disease. The local biotech scene builds on that legacy with founders tackling medicine's toughest challenges," said Julie Gilmore, Ph.D., vice president, and global head of Lilly Gateway Labs and Catalyze360 Portfolio Management. "Access to top-notch lab infrastructure is essential, but success for early-stage companies also requires experienced thought partners who understand the science and can help navigate the challenging journey from discovery through early clinical development."

Anchored by leading academic medical centers and serving a diverse patient population, Philadelphia has evolved as an upper tier life sciences innovation hub where foundational research rapidly advances toward clinical application. With the addition of Philadelphia, Gateway's U.S. footprint now includes four geographic centers of innovation, including Boston, South San Francisco, and San Diego.

Lilly Gateway Labs is part of Lilly Catalyze360, alongside Lilly Ventures, Lilly ExploR&D, and Lilly TuneLab. Since the first Gateway Labs site opened in 2019, resident companies have collectively raised more than $3 billion, fueling progress on over 50 therapeutic programs.

Read also: Eli Lilly joins trillion-dollar club, fueled by weight loss drug demand boom

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News